A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [F-18] CFT
Tekijät: Nurmi E, Ruottinen HM, Kaasinen V, Bergman J, Haaparanta M, Solin O, Rinne JO
Kustantaja: LIPPINCOTT WILLIAMS & WILKINS
Julkaisuvuosi: 2000
Journal: Annals of Neurology
Tietokannassa oleva lehden nimi: ANNALS OF NEUROLOGY
Lehden akronyymi: ANN NEUROL
Vuosikerta: 47
Numero: 6
Aloitussivu: 804
Lopetussivu: 808
Sivujen määrä: 5
ISSN: 0364-5134
DOI: https://doi.org/10.1002/1531-8249(200006)47:6<804::AID-ANA14>3.3.CO;2-6
Tiivistelmä
We studied the rate of progression of striatal dopamine transporter function in Parkinson's disease (PD). Eight patients with early PD without antiparkinsonian medication and 7 healthy volunteers were investigated with [F-18]CFT positron emission tomography (PET). The PET scan was carried out twice at an approximate 2-year interval. The uptake of [F-18]CFT was calculated as a region-cerebellum:cerebellum ratio at 180 to 210 minutes after injection. At the first PET scan, the [F-18]CFT uptake in PD patients in the putamen was 1.45 +/- 0.45 (mean +/- SD) (42% of the control mean) and 2.43 +/- 0.59 in the caudate nucleus (76% of the control mean). The ratios declined by the time of the second PET scan, and the rate of annual decline of the baseline mean in PD patients was 13.1% in the putamen and 12.5% in the caudate nucleus. In controls, the corresponding figures were 2.1% for the putamen and 2.9% for the caudate nucleus. The decline in [F-18]CFT uptake was significantly higher in PD patients than in controls. Thus, dopamine transporter ligands such as [F-18]CFT seem to be sensitive markers for the rate of progression in PD.
We studied the rate of progression of striatal dopamine transporter function in Parkinson's disease (PD). Eight patients with early PD without antiparkinsonian medication and 7 healthy volunteers were investigated with [F-18]CFT positron emission tomography (PET). The PET scan was carried out twice at an approximate 2-year interval. The uptake of [F-18]CFT was calculated as a region-cerebellum:cerebellum ratio at 180 to 210 minutes after injection. At the first PET scan, the [F-18]CFT uptake in PD patients in the putamen was 1.45 +/- 0.45 (mean +/- SD) (42% of the control mean) and 2.43 +/- 0.59 in the caudate nucleus (76% of the control mean). The ratios declined by the time of the second PET scan, and the rate of annual decline of the baseline mean in PD patients was 13.1% in the putamen and 12.5% in the caudate nucleus. In controls, the corresponding figures were 2.1% for the putamen and 2.9% for the caudate nucleus. The decline in [F-18]CFT uptake was significantly higher in PD patients than in controls. Thus, dopamine transporter ligands such as [F-18]CFT seem to be sensitive markers for the rate of progression in PD.
Turun yliopiston Tutkimustietojärjestelmän portaali